Pulmocide
 | |
| Company type | Privately held company |
|---|---|
| Industry | Biopharmaceutical Research, Medical, Drug Discovery |
| Founded | January 2007 |
| Headquarters | Imperial College London, |
Area served | European Union |
Key people | Garth Rapeport, (CEO) Peter Strong (CSO) |
| Website | pulmocide |
Pulmocide is a privately held biopharmaceutical company focusing on the discovery and development of inhaled medicine for the treatment of life-threatening fungal and viral infections of the respiratory tract.[1] The company is based in London and has a laboratory at the Imperial College’s Innovation Hub.[2]
History
Pulmocide was formed in 2007 by Garth Rapeport (CEO) and Pete Strong (CSO) who previously co-founded RespiVert Ltd alongside Peter J. Barnes and Kazuhiro Ito.[3] RespiVert was acquired by a division of Johnson & Johnson in 2010.[3]
Drug development
Pulmocide is conducting phase 2 trials with PC945, a potent inhaled antifungal agent for the treatment of Aspergillus infections of the lung in patients with asthma, cystic fibrosis or following lung transplantation.[4] Positive initial efficacy data for PC945 in treatment refractory Aspergillus infection following lung transplantation is reported.[5] Pulmocide is conducting a study with PC786, an antiviral compound for the treatment of Human orthopneumovirus, formerly Human respiratory syncytial virus (HRSV).[4]
References
- ^ "Company Overview of Pulmocide Ltd". Bloomberg. Retrieved 13 June 2019.
- ^ "British biotech Pulmocide raises £24m in bid to find treatment for deadly lung diseases". The Telegraph. 20 March 2017. Retrieved 13 June 2019.
- ^ a b "J&J buys UK biotech RespiVert". PharmaTimes. 1 June 2010. Retrieved 13 June 2019.
- ^ a b "A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study". Clinicaltrials.gov. 22 December 2017. Retrieved 13 June 2019.
- ^ "Fungal Update Meeting 2019: First Case Report of PC945 Treatment of Refectory Aspergillus Anastomotic Infection in a Lung Transplant Recipient". BEAM Alliance. 19 March 2019. Retrieved 13 June 2019.